

**Tumor Board Tuesday – Dr. Stephanie L. Graff, Dr. Laura Salama, & Dr. Charles Milrod, 11/8/2022:
I/O 1st & Subsequent Lines (Challenging Case in I/O in BC)**

Posttest Rationale

1. **What 1L treatment would you select for a patient with PD-L1+ (CPS = 14), locally advanced (pN+) TNBC and disease recurrence after 4 cycles of adjuvant chemotherapy (dose-dense AC) 8 months previously?**
 - a. Capecitabine
 - b. Dostarlimab
 - c. Pembrolizumab
 - d. **Pembrolizumab + chemo**

Rationale: The NCCN guidelines recommend pembrolizumab + chemotherapy (albumin-bound paclitaxel, paclitaxel, or gemcitabine and carboplatin) as the preferred first-line therapy for patients with TNBC and PD-L1 CPS ≥ 10 . Capecitabine and other chemotherapy regimens are recommended for patients with PD-L1 CPS < 10 , and single-agent pembrolizumab or dostarlimab may be considered for patients with MSI-H/dMMR or TMB-H (pembrolizumab only).

Reference: National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]): Breast Cancer (v4.2022). Updated June 21, 2022. Accessed August 1, 2022.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf